The Humane Cosmetics Act of 2025 makes it unlawful, beginning one year after enactment, to conduct or contract for cosmetic animal testing in the United States and to sell or transport in interstate commerce any cosmetic developed or manufactured using such post‑effective‑date testing. It also bars reliance, for purposes of establishing cosmetic safety under the Federal Food, Drug, and Cosmetic Act, on evidence produced by animal tests conducted after the effective date except in narrowly defined circumstances.
The bill builds a compliance regime around those prohibitions: it sets civil penalties (up to $10,000 per violation as determined by HHS), gives the Secretary of Health and Human Services authority to request records from manufacturers, creates specific exemptions (including tests required by foreign regulators, Secretary‑authorized tests after public notice and comment, products regulated as drugs, and non‑cosmetic regulatory requirements), and preempts state laws that are not identical to the federal scheme. For companies and supply‑chain actors, the practical effects are increased documentation, new evidentiary standards for safety submissions, and potential trade and operational friction where foreign rules require animal data.
At a Glance
What It Does
The bill prohibits most cosmetic animal testing in the U.S. and bans interstate sale or transport of cosmetics developed using such testing conducted after the bill’s effective date. It also prevents the FDA (HHS) from relying on post‑effective‑date animal testing to demonstrate cosmetic safety except under limited, enumerated exemptions.
Who It Affects
Cosmetic manufacturers, ingredient suppliers, contract testing labs, importers and retailers, and the FDA; it also affects developers of non‑animal test methods and foreign regulatory regimes that require animal data.
Why It Matters
This law would force a supply‑chain shift to validated non‑animal safety strategies and heighten recordkeeping and traceability requirements. It sets a federal baseline that limits state variation and creates a formal process for agency exceptions, altering how companies allocate compliance resources and how safety evidence is accepted.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act establishes a clear bright‑line rule: after a one‑year transition, you may not knowingly perform or pay for animal tests in the U.S. to evaluate cosmetics, nor offer for sale or move in interstate commerce cosmetics that were developed or manufactured using such testing performed after that date. That ban is both on the act of testing and on commercially distributing products that were developed using those tests, shifting legal exposure from labs and manufacturers to the whole supply chain.
To prevent the FDA from being used as a backdoor for post‑ban animal data, the bill disallows reliance on any animal test evidence generated after the effective date to establish cosmetic safety under the FD&C Act unless narrow conditions are met. Those conditions require that no non‑animal alternative recognized by a federal agency, ICCVAM, or OECD exists for the relevant safety endpoints, and then additional, tiered exceptions apply (including a Secretary‑authorized testing pathway, recognition that the test was for non‑cosmetic regulatory purposes, or prior non‑cosmetic use of the ingredient with documented history).The Secretary of Health and Human Services gets a specific process for authorizing new animal testing: a written finding that no alternatives exist and that the ingredient presents health concerns, publication of that finding with at least 60 days for public comment, and a written determination after public review that no existing data could substitute for the new tests.
The bill also preserves the right of entities to keep or review animal test data (it does not destroy or prohibit retention of existing evidence), and gives the Secretary power to request records from manufacturers to substantiate claims that an ingredient’s post‑effective‑date animal data fall into one of the narrow exceptions.Enforcement is primarily civil: the Secretary may impose monetary penalties up to $10,000 per violation as determined by the agency, and the statute treats each animal tested and each day a violation continues as a separate offense. The Act also preempts any state or local law that is not identical to the federal prohibitions and exemptions, and it clarifies key definitions—most importantly defining “cosmetic animal testing” as internal or external exposure of live non‑human vertebrates to evaluate cosmetic safety or efficacy, and carrying forward the CFR definition of incidental or "nonfunctional" ingredients.
The Five Things You Need to Know
The ban’s effective date is exactly one year after enactment; after that date it is unlawful to conduct or contract for cosmetic animal testing in the U.S. and to sell or transport in interstate commerce cosmetics developed using such testing.
The FDA cannot rely on animal testing conducted after the effective date to establish cosmetic safety unless no non‑animal alternative is recognized by a federal agency, ICCVAM, or the OECD for the relevant endpoints.
The Secretary may authorize new animal testing only after publishing a written finding and a 60‑day public comment period, and must affirm that no previously generated data could substitute for the new testing.
Civil penalties are discretionary up to $10,000 per violation, with each animal tested and each day of ongoing noncompliance treated as separate offenses for enforcement purposes.
The Act preempts any State or political subdivision law that is not identical to the federal prohibitions and exemptions, and it prohibits States from requiring any cosmetic animal testing not allowed under federal law.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Formally names the statute the “Humane Cosmetics Act of 2025.” This is a housekeeping provision but signals legislative intent and will be the citation used in regulatory and compliance guidance.
Prohibits cosmetic animal testing and downstream sale/transport
Subsection (a) outlaws knowingly conducting or contracting for cosmetic animal testing within the United States beginning one year after enactment. Subsection (b) makes it unlawful to sell, offer for sale, or transport in interstate commerce any cosmetic product that was developed or manufactured using animal testing that occurred or was contracted for in the supply chain after the effective date. Practically, manufacturers and importers must ensure upstream suppliers and contract labs did not use post‑effective‑date animal tests, and retailers face risk if they handle products traced to such testing.
Restricts agency reliance on post‑ban animal data
This provision prevents the Secretary (acting through FDA) from relying on animal test evidence generated after the effective date to establish cosmetic safety unless one of the statutory carve‑outs applies. It ties the availability of animal data to the absence of recognized non‑animal alternatives—explicitly referencing federal agencies, ICCVAM, and OECD—and creates layered conditions for when animal data may be considered for ingredients with prior non‑cosmetic use or when the Secretary makes specific findings. The subsection also clarifies that entities may still review or retain animal test data even if it cannot be used to establish safety.
Exemptions, civil penalties, and records access
Subsection (d) enumerates four exemptions: tests required by a foreign regulator; tests requested or required by the Secretary after a published finding and public comment; tests for products regulated as drugs (chapter V of the FD&C Act); and tests done for non‑cosmetic regulatory purposes. Subsection (e) authorizes civil penalties up to $10,000 per violation and treats each animal and each day as a separate offense. Subsection (f) allows the Secretary to request records that manufacturers relied on to meet specific criteria (notably documentation of prior non‑cosmetic use), requires confirmation of receipt, and preserves FDA’s standard inspection authorities—signaling active administrative oversight.
Preemption and definitions
Subsection (g) preempts state and local laws that are not identical to the federal prohibitions and exemptions and prevents states from ordering testing beyond the federal allowance. Subsection (h) provides key definitions—defining 'cosmetic' by reference to the FD&C Act, limiting 'cosmetic animal testing' to live non‑human vertebrate exposures to skin, eyes or other body parts, and adopting the CFR concept of 'nonfunctional constituent'—which narrows the scope of what counts as a covered test and clarifies applicability to incidental ingredients.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Cruelty‑free cosmetic brands and retailers — They will gain a clearer federal baseline that favors non‑animal testing, reducing competitive pressure from brands that rely on animal tests and increasing the market value of validated non‑animal claims.
- Developers of non‑animal testing methods and contract providers of in vitro and computational toxicology — Demand for validated alternatives (in vitro assays, QSARs, organ‑on‑chip) should increase because FDA reliance hinges on recognized non‑animal options.
- Consumers seeking ethical products — The law raises the bar for supply‑chain verification and creates a regulatory disincentive for post‑effective‑date animal testing, expanding the pool of products that can credibly be marketed as cruelty‑free.
- Animal welfare organizations — The statute substantially reduces the legal space for new cosmetic animal tests in the U.S., aligning policy with long‑standing advocacy goals.
Who Bears the Cost
- Cosmetic manufacturers and ingredient suppliers that continue to rely on animal testing — They must shift to non‑animal strategies or secure narrow exemptions, incurring R&D, validation, and documentation costs.
- Contract testing laboratories that perform vertebrate tests — Labs that specialize in animal studies face loss of domestic business and may need to retool facilities or re‑train staff for alternative methods.
- Importers and retailers — They bear compliance and verification burdens to demonstrate products or ingredients were not developed using post‑effective‑date animal tests, exposing them to supply‑chain audit costs and enforcement risk.
- FDA / HHS — The agency will face new administrative workload: adjudicating exemption requests, reviewing record submissions, conducting inspections, and making complex scientific determinations about alternatives recognition.
Key Issues
The Core Tension
The central dilemma is balancing strong animal‑welfare goals with the regulatory duty to protect consumer health: the bill presses industry and regulators to rely on non‑animal methods, but when uncertainty about human safety remains, it creates a hard choice between allowing animal testing to fill data gaps and keeping animals out of the equation—compounded by traceability, international regulatory conflicts, and the pace at which non‑animal methods gain formal acceptance.
The Act resolves the high‑level policy question—phase out animal testing for cosmetics—while leaving complex operational questions to HHS and industry. Key implementation challenges include supply‑chain traceability (how manufacturers will demonstrate that upstream ingredient testing did not occur after the effective date), evidentiary standards for what counts as a recognized non‑animal alternative, and the administrative burden of reviewing exemption requests and record submissions.
The bill’s reliance on external validation authorities (ICCVAM, OECD) helps anchor scientific standards but also imports whatever lag exists between method development and international recognition, potentially delaying legitimate non‑animal options from qualifying.
International and trade tensions are baked in: the statute permits exemptions for tests required by foreign regulators but simultaneously bars sale or transport of products developed using post‑effective‑date animal tests in U.S. interstate commerce. That creates scenarios where compliance with a foreign market’s testing mandate could make a product unsellable in the U.S., unless an exemption is invoked.
Additionally, the preemption clause prevents states from adopting stricter or different rules, which simplifies the national baseline but eliminates states as laboratories for alternative regulatory designs. Finally, enforcement mechanics—civil penalties calculated per animal and per day—could produce steep aggregate fines for single compliance failures, raising questions about proportionality and administrative discretion in penalty assessments.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.